The safety of atypical antipsychotics: does QTc provide all the answers?

Author： Nielsen Jimmi  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.3, 2011-05, pp. : 341-344

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NMS occurs with all atypical antipsychotics − ADRAC

By  

Reactions Weekly, Vol. 1, Iss. 1146-1147, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The safety and tolerability of atypical antipsychotics in bipolar disorder

By Seemüller Florian   Forsthoff Anna   Dittmann Sandra   Born Christoph   Bernhard Britta   Severus W Emanuel   Grunze Heinz  

Expert Opinion on Drug Safety, Vol. 4, Iss. 5, 2005-09 ,pp. : 849-868

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review

By  

Current Clinical Pharmacology, Vol. 8, Iss. 3, 2013-08 ,pp. : 256-264

Bentham Science Publishers

Access to resources Recommend Favorite

Drug metabolism and atypical antipsychotics

By Prior T.I.   Chue P.S.   Tibbo P.   Baker G.B.  

European Neuropsychopharmacology, Vol. 9, Iss. 4, 1999-06 ,pp. : 301-309

Elsevier

Access to resources Recommend Favorite

Tolerability of Atypical Antipsychotics

By Stanniland C.   Taylor D.  

Drug Safety, Vol. 22, Iss. 3, 2000-03 ,pp. : 195-214

Adis International

Access to resources Recommend Favorite